Current Edition


Deciphera details stomach cancer flop against Pfizer’s Sutent, cracking the door open for off-label use

Deciphera Pharmaceuticals recently took a serious hit to its billion-dollar hopeful cancer drug Qinlock. As the company undertakes a round of layoffs to deal with the …

Continue Reading →

Totus tots up $40M in series A funding to go after competitive cancer space

Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to …

Continue Reading →

The University of Texas Md Anderson Cancer Center and Nanobiotix have an agreement to run Immunotherapeutic Pre-Clinical Research in Lung Cancer combining Nbtxr3 and Nivolumab

 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate …

Continue Reading →